Phase II Trial With Safety-Run-In of MEK Inhibitor AS703026 In Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies.

Trial Profile

Phase II Trial With Safety-Run-In of MEK Inhibitor AS703026 In Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Dec 2013 Planned end date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 22 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top